louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01535079: Acute Sore Throat Pain Study
Official title: Analgesic Profile of 3 New Ibuprofen Lozenges (V0498TA01A 15 mg, 25 mg, 35 mg) After Single Administration in Acute Sore Throat Pain
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Sore Throat Pain
Keywords: sore throat pain
tonsillopharyngitis
upper respiratory tract infection
Lead sponsor: Pierre Fabre Medicament
Sponsor class: INDUSTRY
First posted: 2012-02-17
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: "Sore throat is one of the most common complaints encountered in clinical practice. And in 65% of cases, the infection is thought to be viral in nature.

The aim of this study is to evaluate the analgesic profile of 3 Ibuprofen lozenges after single administration in acute sore throat pain."


Eligibility criteria: Inclusion Criteria:

* male or female patients 18 years and older
* patients with a sore throat associated or not with an Upper Respiratory Tract Infection ≥ 24 hours and ≤ 5 days duration, in the absence of Streptococcus group A

Exclusion Criteria:

* patients with hypersensitivity to Ibuprofen or other NSAIDs or the excipients.
* patients having used analgesics or antiseptics or any topical throat treatment or any local medication containing a local oral anaesthetic within 6 hours before study entry and who use analgesics more than ≥ 3 times per week.
* patients having used any anti inflammatory treatment or any long-acting or slow release analgesics within 12 hours before study entry
* patients having taken antibiotics within 14 days before study entry.

Primary outcomes:
measure: Change from baseline of Sore Throat Pain Intensity Scale
timeFrame: 60 minutes
Secondary outcomes:
measure: Change from baseline of Sore Throat Pain relief Scale
timeFrame: up to 360 minutes
measure: Change of Sore Throat Pain Intensity Scales
timeFrame: up to 360 minutes
measure: Local tolerability examination
timeFrame: Baseline (before drug intake) and 360 minutes
measure: General tolerability (reported adverse events)
timeFrame: Baseline (before drug intake) and 360 minutes
Other outcomes:
Locations:
city: Gières
country: France
facility: Eurofins Optimed
city: Pierre Bénite
country: France
facility: Eurofins Optimed Lyon
city: Erfurt
country: Germany
city: Cardiff
country: United Kingdom
Study officials:
References:
Clinical trial NCT02394379: Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL
Official title: A Prospective, Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber Intraocular Lens (IOL)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cataract
Lead sponsor: Bausch & Lomb Incorporated
Sponsor class: INDUSTRY
Collaborators: name: Bausch Health Americas, Inc.
First posted: 2015-03-20
Enrollment: 600
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects will be chosen from 30-50 clinical sites in the US. All subjects who meet Eligibility Criteria (below) will be consecutively offered enrollment until the site meets the maximum number of enrollees.

Brief summary: To evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery.

Detailed description: The objective of this post approval safety study is to evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery at up to three years post implantation.

Eligibility criteria: Inclusion Criteria:

* Subjects who are able and willing to comply with the follow-up schedule
* Subjects must have a clinically documented diagnosis of age-related cataract that is considered amenable to treatment with standard phacoemulsification/extracapsular cataract extraction
* Subjects must require a lens power from 4 to 33 D
* Subjects must have a Best Corrected Visual Acuity (BCVA) equal to or worse than 20/40, with or without a glare source

Exclusion Criteria:

* Subjects with any anterior segment pathology in the study eye likely to increase the risk of complications from phacoemulsification cataract surgery
* Subjects with associated ocular conditions which could affect the stability of the IOL
* Subjects with clinically significant irregular corneal astigmatism in the study eye

Primary outcomes:
measure: Incidence of clinically significant IOL vaulting
timeFrame: Up to 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Bausch & Lomb Incorporated
state: New York
Study officials:
affiliation: Valeant Pharmaceuticals NA / Bausch & Lomb
name: Anya Loncaric
role: STUDY_DIRECTOR
References:
Clinical trial NCT00202579: Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure
Official title: Evaluation of the Effects on Peripheral and Central Haemodynamics Parameters, Safety, and Tolerance of Three-hour Intravenous Perfusion (0.1 mg/kg) of Ivabradine Given to Severe Congestive Heart Failure Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Heart Failure, Congestive
Lead sponsor: Servier
Sponsor class: INDUSTRY
First posted: 2005-09-20
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure


Eligibility criteria: Inclusion Criteria:

* systolic congestive heart failure
* sinus rhythm, HR \>= 80bpm

Exclusion Criteria:

* unstable cardiovascular condition

Primary outcomes:
measure: Haemodynamic parameters
measure: Twelve-lead ECG
measure: Systolic and diastolic blood pressure
Secondary outcomes:
measure: Echocardiography
measure: Neurohormones
Other outcomes:
Locations:
city: Pavia
country: Italy
facility: Policlinico San Matteo
Study officials:
affiliation: Policlinico San Matteo
name: Luigi Tavazzi, Pr
role: STUDY_CHAIR
References:
Clinical trial NCT05442879: Knowledge Translation Intervention for ACL Injury Prevention Program in Youth Soccer
Official title: The Effects of a Knowledge Translation Intervention With an ACL Prevention Program on Implementation, Injury Rates, and Performance in Youth Soccer Players
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anterior Cruciate Ligament Injuries
Lower Extremity Problem
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Community Foundation of Greater Flint
First posted: 2022-07-05
Enrollment: 671
Sex: ALL
Minimum age (years): 14
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Anterior cruciate ligament (ACL) injuries of the knee are common in youth soccer players, and show an even higher prevalence in female soccer players. Clinical practice guidelines recommend ACL injury prevention programs (ACL-IPP) to reduce injury risk, yet implementation in amateur youth soccer is low, reducing actual real-world effectiveness. This trial is a pragmatic effectiveness trial for ACL injury prevention for amateur youth soccer players, using a knowledge translation intervention with the Knowledge-to-Action Framework.

Detailed description: ACL injury prevention programs (ACL-IPP) are exercise programs recommended by clinical practice guidelines that have been shown to reduce the risk of an ACL injury. However, implementation of these programs is low, which reduces the real-world effectiveness of these programs. This project will assess a knowledge translation intervention with youth soccer programs for implementation of ACL-IPPs utilizing the Knowledge-to-Action Framework. The main educational intervention will be a knowledge translation (KT) intervention between the researchers, and coaches/players of youth soccer programs within the state of Michigan. Specifics of the knowledge translation intervention will or may include focus groups, surveys, in-person training, video handouts, and paper handouts. This will be compared to coaches/teams that are offered a handout that describes an evidence-based ACL-IPP.

Eligibility criteria: Inclusion Criteria:

* Amateur youth soccer organizations within southern Michigan.

Exclusion Criteria:

* Players above the age of 19 or below the age of 14
* Teams that have dedicated medical staffing

Primary outcomes:
measure: Uptake of ACL-IPP
timeFrame: up to 2 years
measure: Number of ACL injuries
timeFrame: up to 2 years
Secondary outcomes:
measure: Change in 5-10-5 test time
timeFrame: 2-4 months
measure: Change in horizontal jump distance
timeFrame: 2-4 months
measure: Change in 10 meter forward run time
timeFrame: 2-4 months
measure: Number of time-loss lower extremity injuries
timeFrame: up to 2 years
Other outcomes:
Locations:
city: Flint
country: United States
facility: University of Michigan-Flint
state: Michigan
Study officials:
References:
Clinical trial NCT04682379: Adolescent Idiopathic Scoliosis and Proprioceptive Defect
Official title: The Role of Proprioceptive Deficits in the Progression of Adolescent Idiopathic Scoliosis
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Adolescent Idiopathic Scoliosis
Idiopathic Scoliosis
Scoliosis
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
First posted: 2020-12-23
Enrollment: 166
Sex: ALL
Minimum age (years): 10
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Potential participants will be identified by consecutively screening in the clinics of the speciality outpatient department at the Hospital for all patients with scoliosis

Brief summary: This is the first clinical study to examine the spinal and peripheral proprioceptive deficits in longitudinal terms among subjects with adolescent idiopathic scoliosis.


Eligibility criteria: Inclusion Criteria:

* diagnosis of adolescent idiopathic scoliosis
* did not receive or failed conservative treatment

Exclusion Criteria:

* spinal injury, fracture, or spinal tumour
* neurological deficit
* brain or spinal cord abnormality
* developmental delay
* psychological disorder

Primary outcomes:
measure: Repositioning errors
timeFrame: Baseline
measure: Repositioning errors
timeFrame: One year follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The Duchess of Kent Children's Hospital
Study officials:
affiliation: The University of Hong Kong
name: Kenneth Cheung
role: PRINCIPAL_INVESTIGATOR
References:
citation: Lau KKL, Law KKP, Kwan KYH, Cheung JPY, Cheung KMC, Wong AYL. Timely Revisit of Proprioceptive Deficits in Adolescent Idiopathic Scoliosis: A Systematic Review and Meta-Analysis. Global Spine J. 2022 Oct;12(8):1852-1861. doi: 10.1177/21925682211066824. Epub 2021 Dec 15.
citation: Lau KKL, Law KKP, Kwan KYH, Cheung JPY, Cheung KMC. Proprioception-related gene mutations in relation to the aetiopathogenesis of idiopathic scoliosis: A scoping review. J Orthop Res. 2023 Dec;41(12):2694-2702. doi: 10.1002/jor.25626. Epub 2023 Jun 4.
citation: Lau KK, Kwan KY, Cheung JP, Chow W, Law KK, Wong AY, Chow DH, Cheung KM. Reliability of a three-dimensional spinal proprioception assessment for patients with adolescent idiopathic scoliosis. Eur Spine J. 2022 Nov;31(11):3013-3019. doi: 10.1007/s00586-022-07338-0. Epub 2022 Aug 3.
Clinical trial NCT05615779: Personalized B-fructan Diet in Inflammatory Bowel Disease Patients
Official title: The Fibre Study: RCT of Personalized Fibre Diet in IBD
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Inflammatory Bowel Diseases
Ulcerative Colitis
Lead sponsor: University of Manitoba
Sponsor class: OTHER
First posted: 2022-11-14
Enrollment: 600
Sex: ALL
Minimum age (years): 6
Maximum age (years): 39
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.


Eligibility criteria: Inclusion Criteria:

* Children (age 6-17) or young adults (age 18-39).
* Known or suspected UC or IBDU \[there will be 2 control group: non-IBD (undergoing colonoscopy but found not to have IBD; and healthy (no GI symptoms, so not required to have colonoscopy; could be family members)\]
* For UC: Remission-mild-moderate disease: Mayo score \<10
* Clinical indication for sedated colonoscopy
* Disease location: E2-E4
* Stable treatment (not on steroids; biologics or immunomodulator not changed in last month)
* High likelihood that patients will be able to collect all samples and provide all data

Exclusion Criteria:

* Use of antibiotics for a week or more over the last 3 months
* Use of probiotics or prebiotics at pharmacological doses (adding fibre sources to food or probiotics in yogurt, for example, are allowed)
* History of abdominal surgery, including appendectomy
* Documented enteric infection during the 3 months prior to endoscopy
* Presence of non-IBD bowel conditions (e.g., celiac), anatomical or mucosal abnormalities, motility disorder
* Presence of a systemic disease requiring treatment (cancer, ischemic heart disease, kidney failure, etc)
* Proctitis (E1)
* Systemic steroids (above 10 mg/day of Prednisone)
* Topical therapy within 1 week of endoscopy
* Recent change in IBD treatment (started biologics or IM over the last month)
* Pregnancy or planning to become pregnant during the study
* Inability to understand or sign the consent

Primary outcomes:
measure: Diet tolerability
timeFrame: 4 weeks
Secondary outcomes:
measure: Inflammatory response to diet
timeFrame: 1 week, 4 weeks, 8 weeks, 12 weeks
measure: Microbiota changes in response to diet
timeFrame: 1 week, 4 weeks, 8 weeks, 12 weeks
Other outcomes:
Locations:
city: Edmonton
country: Canada
facility: University of Alberta Hospital
state: Alberta
city: Winnipeg
country: Canada
facility: Health Sciences Centre Hospital
state: Manitoba
Study officials:
References:
Clinical trial NCT06103084: Effectiveness of Local Food Solutions for the Prevention of Acute Malnutrition in Tigray, Northern Ethiopia (ELOFSAM)
Official title: Acceptability and Effectiveness of Local Food Solutions for the Prevention of Acute Malnutrition in Tigray, Northern Ethiopia (ELOFSAM)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Acute Malnutrition in Childhood
Lead sponsor: Mekelle University
Sponsor class: OTHER
Collaborators: name: Tigray Development Association
name: Mums for Mums
name: Tigray Health Research Institute
name: Tigray Health Bureau
name: UNICEF Tigray Office
First posted: 2023-10-26
Enrollment: 7530
Sex: ALL
Minimum age (years): 6
Maximum age (years): 23
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The lack of diversified and enriched complementary foods is one of the key causes of the high burden of acute malnutrition among 6-23 months old children in Ethiopia. Thus, a new innovative way of diversifying and enriching complementary foods is essential in communities where vulnerable populations are likely to have nutrient gaps in their typical diets and multiple micronutrient deficiencies. The purpose of this project is to investigate the acceptability and effectiveness of locally produced cereal based foods (LP-CBFs) and small quantity lipid based nutrient supplements (SQ-LNS) as preventive interventions to effectively reduce the burden of acute malnutrition among 6-23 months old children in the post conflict settings of Tigray, Northern Ethiopia.


Eligibility criteria: Inclusion Criteria:

* All 6-23 months old children

Exclusion Criteria:

* 6-23 months old children with severe acute malnutrition.

Primary outcomes:
measure: Acute Malnutrition
timeFrame: six months
Secondary outcomes:
Other outcomes:
Locations:
city: Mek'ele
country: Ethiopia
facility: Tigray Health Research Institute
state: Tigray
Study officials:
affiliation: Tigray Health Research Institute
name: Hayelom Kahsay, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00251784: Healthy Volunteer Study of Sildenafil Effects Upon Vision
Official title: A Double-Blind, Randomised, Placebo Controlled Healthy Volunteer Study to Investigate the Nature and Origin of the Disturbance of Vision Induced by Single Oral Doses of Sildenafil
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Blindness
Lead sponsor: University of Cambridge
Sponsor class: OTHER
First posted: 2005-11-10
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: ECT

Brief summary: Patients sometimes report subjective visual effects when taking sildenafil. Our study set out to measure these in a controlled setting. Subjects were asked to detect patterns presented on a monitor screen.


Eligibility criteria: Inclusion Criteria: male -

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Cambridge
name: Morris J Brown, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Cambridge
name: John Mollon, FRS
role: STUDY_DIRECTOR
References:
Clinical trial NCT02771184: Computerized Lung Sound Analysis
Official title: Computerized Lung Sound Analysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pneumothorax
Pulmonary Fibrosis
Lead sponsor: Medical University of Graz
Sponsor class: OTHER
Collaborators: name: Graz University of Technology
First posted: 2016-05-13
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: This clinical trial is conducted within the research project 'Computerized Lung Sound Analysis'. The research goal is the development of a system enabling the automatic classification of lung sounds, which will result in a decision support system for physicians.

The objective of this trial is to create a small lung sound corpus, enabling the development of a prototype of the described system. Therefore, investigators record lung sounds with several lung sound transducers distributed on the posterior chest of human test subjects.

Detailed description: In this clinical trial investigators record lung sounds over the posterior chest of human test subjects. The subjects are either lung-healthy (control group) or subjects with pneumothorax condition or pulmonary fibrosis. The lung sounds are recorded in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. For each subject investigators simultaneously record 30 seconds of the airflow signal and the lung sounds from 16 lung sound transducers.

Eligibility criteria: Inclusion Criteria:

General:

* Smoker and non-smoker
* 'Lung-healthy' subjects (control group), subjects with pneumothorax or subjects with pulmonary fibrosis

Additional for 'lung-healthy' subjects:

* COPD \< 3 (GOLD Criteria)

Exclusion Criteria:

General:

* Body Mass Index \> 30
* Preceding thoracic surgery
* Non-cooperation of the subject
* Intubated or tracheostomized subjects

Additional for 'lung-healthy' subjects:

* Disease of the respiratory system
* Taking medication influencing the respiration

Primary outcomes:
measure: 16-Channel Lung Sound Recordings and synchronous Airflow Recording
timeFrame: 30 Seconds
Secondary outcomes:
Other outcomes:
Locations:
city: Graz
country: Austria
facility: Medical University of Graz
Study officials:
affiliation: Medical University of Graz
name: Freyja-Maria Smolle-Juettner, Univ.-Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02071784: Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Official title: Etude Comparative en Imagerie Par résonnance magnétique et Par Enregistrement électroencéphalographique du Couplage Neurovasculaire Dans l'Angiopathie Cadasil
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: CADASIL
Lead sponsor: Institut National de la Santé Et de la Recherche Médicale, France
Sponsor class: OTHER_GOV
First posted: 2014-02-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: CADASIL patients compared to age-matched controls (two groups)

Brief summary: The aim of this study is to investigate using fMRI methods, EEG and dedicated mathematical models, the potential alterations of neurovascular coupling in CADASIL.

Detailed description: Comparison study of parameters derived from mathematical models of neurovascular coupling and obtained using fMRI (Bold signal, ASL and EEG).

Eligibility criteria: Inclusion Criteria:

* CADASIL group: typical NOTCH3 mutation, age less than 60 years, rankin score at 0-1, active social insurance

Exclusion Criteria:

* MRI contra-indications and use of any treatment known to interfere with neurovascular coupling, pregnancy, lack of informed consent

Primary outcomes:
measure: model-derived parameters of neurovascular coupling
timeFrame: one time point
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: CENIR, Hopital Pitié Salpetriere
Study officials:
affiliation: INSERM and APHP
name: Hugues Chabriat, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00429884: Studies of Disorders and Mechanisms Related to Atrial Fibrillation Before and After DC-Conversion.
Official title: Studies of Disorders and Mechanisms Related to Atrial Fibrillation Before and After DC-Conversion: Polysomnography, Heart Rate Variability and 24h Holter.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
Lead sponsor: Umeå University
Sponsor class: OTHER
First posted: 2007-02-01
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to investigate if breathing disorders are related to atrial fibrillation and if it is possible to predict recurrence of atrial fibrillation after DC-conversion by changes in heart rate variability and 24 hour ECG.


Eligibility criteria: Inclusion Criteria:

* persistent atrial fibrillation
* scheduled for electrical cardioversion

Exclusion Criteria:

* known obstructive sleep apnea

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Umeå
country: Sweden
facility: Heart Centre, Umeå University Hospital
Study officials:
affiliation: Heart Centre, Umeå University Hospital
name: Steen M Jensen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Heart Centre, Umeå University Hospital
name: Niklas G Höglund, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Umeå University Hospital
name: Karl Franklin, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hoglund N, Sahlin C, Kesek M, Jensen SM, Franklin KA. Cardioversion of atrial fibrillation does not affect obstructive sleep apnea. Ups J Med Sci. 2017 Jun;122(2):114-118. doi: 10.1080/03009734.2017.1291545. Epub 2017 Mar 14.